TOKYO, Mar 17 (Pulse News Wire) – RIBOMIC Inc. (4591.T) resolved to adjust the funding allocation dates for equity warrants issued in previous years during its board meeting held today.
The changes pertain to funds raised through the issuance of the 15th and 17th tranches of equity warrants with exercise price adjustment clauses. For the 15th tranche of equity warrants, the company altered the planned expenditure schedule due to ongoing clinical development costs related to achondroplasia phase II trials. Specifically, remaining funds will now be allocated towards long-term administration tests within the phase II trial framework. Previously disclosed adjustments included modifications based on pipeline development progress and strategic priorities.
Regarding the 17th tranche of equity warrants, the company revised the spending timeline to align with future clinical trial plans, focusing on CMC development and toxicity testing for RBM-006, which targets proliferative vitreoretinopathy (PVR). The shift reflects advancements made in non-clinical studies, such as eye hemorrhage inhibition observed in mouse diabetic retinopathy models. Key figures for the adjusted allocations are as follows: 15th Tranche: - Total allocated amount: - New allocation for drug delivery system aptamer research: (previously ) 17th Tranche: - Total allocated amount: - Allocated amount for RBM-006 research: (previously ) - Remaining balance for operational expenses remains unchanged at but has shifted to later dates. These adjustments are expected to enhance the efficiency and alignment of expenditures with current project milestones without impacting the fiscal year ending March 2026 performance metrics.
🟢 Confidence: High AI-translated content.